These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6628700)

  • 21. Luteolin induces N-acetylation and DNA adduct of 2-aminofluorene accompanying N-acetyltransferase activity and gene expression in human bladder cancer T24 cell line.
    Su CC; Chen GW; Yeh CC; Yang MD; Hung CF; Chung JG
    Anticancer Res; 2003; 23(1A):355-62. PubMed ID: 12680237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A unique pharmacogenetic expression of the N-acetylation polymorphism in the inbred hamster.
    Hein DW; Omichinski JG; Brewer JA; Weber WW
    J Pharmacol Exp Ther; 1982 Jan; 220(1):8-15. PubMed ID: 7053425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical evaluation of N-acetyltransferase activity in children with various forms of diffuse connective tissue diseases].
    Ermakova TM; Kovaleva VL; Brezhneva EG; Evstaf'eva OL; Alekseev IuV
    Pediatriia; 1983 Nov; (11):10-3. PubMed ID: 6669424
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer.
    Cartwright RA; Glashan RW; Rogers HJ; Ahmad RA; Barham-Hall D; Higgins E; Kahn MA
    Lancet; 1982 Oct; 2(8303):842-5. PubMed ID: 6126711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acetylation phenotype in patients with systemic lupus erythematosus].
    Iakushkevich TN; Tareeva IE; Tuganbekova SK; Kovaleva VL; Evstaf'eva OL
    Ter Arkh; 1985; 57(8):82-4. PubMed ID: 3865448
    [No Abstract]   [Full Text] [Related]  

  • 27. [Significance of N-acetyltransferase phenotype in development of bladder neoplasms].
    Wolf H; Lower GM; Bryan GT
    Ugeskr Laeger; 1980 Feb; 142(6):382-5. PubMed ID: 7368384
    [No Abstract]   [Full Text] [Related]  

  • 28. N-acetyltransferase phenotypes in bladder tumour patients with and without carcinoma in situ in selected site biopsies.
    Mommsen S; Wolf H
    Scand J Urol Nephrol; 1985; 19(3):203-4. PubMed ID: 4070990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients.
    Ishizu S; Hashida C; Hanaoka T; Maeda K; Ohishi Y
    Jpn J Cancer Res; 1995 Dec; 86(12):1179-81. PubMed ID: 8636007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isoniazid acetylation metabolic ratio during maturation in children.
    Pariente-Khayat A; Rey E; Gendrel D; Vauzelle-Kervroëdan F; Crémier O; d'Athis P; Badoual J; Olive G; Pons G
    Clin Pharmacol Ther; 1997 Oct; 62(4):377-83. PubMed ID: 9357388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biochemical indices of genetic susceptibility to cancer. Acetylation phenotype and bladder cancer.
    Hanke J; Krajewska B
    Pol J Occup Med; 1988; 1(4):306-11. PubMed ID: 2979565
    [No Abstract]   [Full Text] [Related]  

  • 32. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population.
    Mommsen S; Barfod NM; Aagaard J
    Carcinogenesis; 1985 Feb; 6(2):199-201. PubMed ID: 3971485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Acetyltransferase phenotype of patients with bladder cancer.
    Karakaya AE; Cok I; Sardas S; Gögüs O; Sardas OS
    Hum Toxicol; 1986 Sep; 5(5):333-5. PubMed ID: 3770769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lupus erythematosus disseminatus and active isoniazid levels. A study of 47 cases].
    Godeau P; Aubert M; Imbert JC; Herreman G
    Ann Med Interne (Paris); 1973 Mar; 124(3):181-6. PubMed ID: 4716710
    [No Abstract]   [Full Text] [Related]  

  • 35. NAT2 and bladder cancer--response.
    Pesch B; Bruening T; Vineis P
    Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):562. PubMed ID: 24381185
    [No Abstract]   [Full Text] [Related]  

  • 36. NAT2 and bladder cancer--letter.
    Golka K; Blaszkewicz M; Selinski S; Hengstler JG; Bolt HM
    Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):561. PubMed ID: 24381186
    [No Abstract]   [Full Text] [Related]  

  • 37. Normal distribution of acetylation phenotypes in systemic lupus erythematosus.
    Vansant J; Woosley RL; John JT; Sergent JS
    Arthritis Rheum; 1978 Mar; 21(2):192-5. PubMed ID: 637885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-Acetyltransferases and the susceptibility to benzidine-induced bladder carcinogenesis.
    Wang CY; King CM
    Int J Cancer; 2007 Jun; 120(11):2523-4. PubMed ID: 17311263
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply to the letter to the Editor: "N-Acetyltransferases and the susceptibility to benzidine-induced bladder carcinogenesis".
    Carreón T; Kadlubar FF; Ruder AM; Schulte PA; Hayes RB; Waters M; Grant DJ; Boissy R; Bell DA; Hemstreet GP; Yin S; Lemasters GK; Rothman N
    Int J Cancer; 2007 Oct; 121(7):1637-9; author reply 1640-1. PubMed ID: 17583575
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pharmacokinetics of drug preparations metabolized by N-acetyltransferase].
    Skakun NP
    Klin Med (Mosk); 1982 Jan; 60(1):24-7. PubMed ID: 6122757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.